地舒单抗与口服阿仑膦酸钠治疗日本老年骨质疏松女性的成本效果比较
研究构建马尔可夫微观模拟模型,比较日本社区居住、无既往髋部或椎体骨折的老年骨质疏松女性中,每6个月皮下注射地舒单抗5年与每周口服阿仑膦酸钠5年的成本效果。结果显示,在75岁和80岁起始治疗时地舒单抗具有成本节约优势,在65岁和70岁时也处于常规支付意愿阈值内。
要点
- 地舒单抗每6个月1次用5年 vs 阿仑膦酸钠每周1次用5年,在75岁和80岁起始治疗时具有成本节约优势。
- 65岁和70岁起始治疗时,地舒单抗的增量成本效果比(ICER)分别为每质量调整生命年(QALY)25,700美元和5000美元(社会视角)。
- 在每QALY 50,000美元的支付意愿阈值下,地舒单抗具有成本效果的概率为89%–100%。
核心结论
- 在75岁和80岁起始治疗时,地舒单抗相比阿仑膦酸钠具有成本节约优势。
- 在65岁和70岁起始治疗时,地舒单抗的ICER分别为每QALY 25,700美元和5000美元(社会视角),在其他两个视角下未超过每QALY 50,000美元的支付意愿阈值。
- 在每QALY 50,000美元的支付意愿阈值下,地舒单抗具有成本效果的概率为89%–100%。
研究设计与样本
- 研究采用马尔可夫微观模拟模型,在假设的日本社区居住、无既往髋部或椎体骨折的老年骨质疏松女性队列中进行分析。
- 比较每6个月皮下注射地舒单抗5年与每周口服阿仑膦酸钠5年,起始治疗年龄分别为65、70、75和80岁,时间跨度为终生。
- 分析从社会、医疗部门和政府三个视角进行,计算增量成本效果比(ICER,2016年美元每QALY)。
主要发现
- 在75岁和80岁起始治疗时,从三个视角分析地舒单抗相比阿仑膦酸钠均具有成本节约优势。
- 在65岁和70岁起始治疗时,社会视角下地舒单抗相比阿仑膦酸钠的ICER分别为每QALY 25,700美元和5000美元。
- 在65岁和70岁起始治疗时,从医疗部门和政府视角分析,地舒单抗的ICER未超过每QALY 50,000美元的支付意愿阈值。
- 确定性敏感性分析显示,结果对地舒单抗降低髋部骨折和临床椎体骨折的效果以及地舒单抗相比阿仑膦酸钠的不持续率比值的变化敏感。
- 概率敏感性分析显示,在每QALY 50,000美元的支付意愿阈值下,地舒单抗相比阿仑膦酸钠具有成本效果的概率为89%–100%。
关键数值与推荐
- 75岁和80岁起始治疗时,地舒单抗相比阿仑膦酸钠在三个视角下均为成本节约。
- 65岁起始治疗时,社会视角下地舒单抗相比阿仑膦酸钠的ICER为每QALY 25,700美元。
- 70岁起始治疗时,社会视角下地舒单抗相比阿仑膦酸钠的ICER为每QALY 5000美元。
- 在每QALY 50,000美元的支付意愿阈值下,地舒单抗相比阿仑膦酸钠具有成本效果的概率为89%–100%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 确定性敏感性分析显示结果对地舒单抗降低髋部骨折和临床椎体骨折的效果以及地舒单抗相比阿仑膦酸钠的不持续率比值的变化敏感。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: We constructed a Markov microsimulation model among hypothetical cohorts of community-dwelling elderly osteoporotic Japanese women without prior hip or vertebral fractures over a lifetime horizon. Compared with weekly oral alendronate for 5 years, denosumab every 6 months for 5 years is cost-saving or cost-effective at a conventionally accepted threshold. INTRODUCTION: The objective of the study was to examine the cost-effectiveness of subcutaneous denosumab every 6 months for 5 years compared with weekly oral alendronate for 5 years in Japan. METHODS: We calculated incremental cost-effectiveness ratios [ICERs] (2016 US dollars [$] per quality-adjusted life year [QALY]), using a Markov microsimulation model among hypothetical cohorts of community-dwelling osteoporotic Japanese women without prior hip or vertebral fractures at various ages of therapy initiation (65, 70, 75, and 80 years) over a lifetime horizon from three perspectives: societal, healthcare sector, and government. RESULTS: Denosumab was cost-saving compared with alendronate at ages 75 and 80 years from any of the three perspectives. The ICERs of denosumab compared with alendronate were $25,700 and $5000 per QALY at ages 65 and 70 years from a societal perspective and did not exceed a willingness-to-pay of $50,000 per QALY from the other two perspectives. In deterministic sensitivity analyses, results were sensitive to changes in the effectiveness of denosumab for reducing hip fracture and clinical vertebral fracture and the rate ratio of non-persistence with denosumab compared to alendronate. In probabilistic sensitivity analyses, the probabilities of denosumab being cost-effective compared with alendronate were 89-100% at a willingness-to-pay of $50,000 per QALY. CONCLUSIONS: Among community-dwelling elderly osteoporotic women in Japan, denosumab every 6 months for 5 years is cost-saving or cost-effective at a conventionally accepted threshold of willingness-to-pay at all ages examined, compared with weekly alendronate for 5 years. This study provides insight to clinicians and policymakers regarding the relative economic value of osteoporosis treatments in elderly women.
引用
- Mori T, Crandall CJ, Ganz DA, et al. Cost-effectiveness of denosumab versus oral alendronate for elderly osteoporotic women in Japan. Osteoporos Int. 2017. PMID: 28210776. doi:10.1007/s00198-017-3940-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。